Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.
Open Access
- 1 March 2025
- journal article
- Published by American Psychological Association (APA) in Neuropsychology
- Vol. 39 (3) , 248-258
Abstract
Objectively defined subtle cognitive decline (Obj-SCD) is an emerging classification that may identify individuals at risk for future decline and progression to Alzheimer's disease prior to a diagnosis of mild cognitive impairment (MCI). Growth-associated protein 43 (GAP-43), a cerebrospinal fluid (CSF) marker of synaptic dysfunction, has been shown to relate to an increased risk of converting to dementia, although it is unclear whether GAP-43 alterations may be detected in pre-MCI stages. Therefore, in the present study, we examined CSF GAP-43 levels among individuals with Obj-SCD cross-sectionally and also examined whether baseline GAP-43 predicts future functional decline. Six hundred forty-four participants from the Alzheimer's Disease Neuroimaging Initiative were divided into six groups based on (a) cognitive status (cognitively unimpaired [CU], Obj-SCD, or MCI) and (b) Aβ status (+ or -). The CU- group had lower baseline GAP-43 than all Aβ+ groups, but not the other Aβ- groups. Higher GAP-43 levels were associated with faster decline across the entire sample. When moderation by group was examined, higher GAP-43 at baseline predicted faster functional decline for the Obj-SCD+ and MCI+ groups, compared to the CU- group. Results extend prior work investigating biomarker associations in Obj-SCD to GAP-43 and show that high baseline CSF GAP-43 is associated with a faster rate of functional decline in Aβ+ individuals who are classified as Obj-SCD or MCI. Importantly, our findings further demonstrate that CSF GAP-43 is associated with early and subtle cognitive changes detectable before the onset of MCI. (PsycInfo Database Record (c) 2025 APA, all rights reserved).Keywords
Funding Information
- U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service (2 1IK2CX001865, 1I01CX001842)
- National Institutes of Health (R01 AG063782, R03 AG070435, U01 AG024904)
- Alzheimer’s Association (AARF-17-528918, AARG-18-566254)
- Department of Defense (W81XWH-12-2-0012)
This publication has 45 references indexed in Scilit:
- Restriction in complex activities of daily living in MCINeurology, 2006
- Mild Cognitive Impairment and 10‐Year Trajectories of Disability in the Iowa Established Populations for Epidemiologic Studies of the Elderly CohortJournal of the American Geriatrics Society, 2005
- Differential loss of synaptic proteins in Alzheimer's disease: Implications for synaptic dysfunctionJournal of Alzheimer’s Disease, 2005
- Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive ImpairmentJournal of Internal Medicine, 2004
- Subfield-specific increase in brain growth protein in postmortem hippocampus of Alzheimer's patientsNeuroscience, 2004
- Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer's disease: an immunohistochemical and quantitative studyJournal of Neural Transmission, 2000
- Neurochemical Dissection of Synaptic Pathology in Alzheimer's DiseaseInternational Psychogeriatrics, 1998
- Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 alleleJournal of Neural Transmission, 1996
- Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairmentAnnals of Neurology, 1991
- Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severityAnnals of Neurology, 1990